Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

NCT05586100 is registered in ClinicalTrials.gov with Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University as lead sponsor.

NCT NCT05586100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05586100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study
Lead sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 13, 2022
Completion date
April 28, 2026
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patients with locally recurrent resectable head and neck squamous cell carcinoma